Calidi Biotherapeutics, INC S-1 registration statements

Calidi Biotherapeutics, a clinical-stage biotechnology company, is offering up to 1.2 million common stock units and pre-funded warrant units to raise approximately $5.1 million in net proceeds, as it faces recurring losses and substantial doubt about its ability to continue as a going concern.

Calidi Biotherapeutics, a clinical-stage biotechnology company, filed an S-1 registration statement for the resale of up to 6.35 million common shares, detailing its novel oncolytic virus platforms, recent management changes, and persistent financial challenges including substantial operating losses and a going concern warning.

Calidi Biotherapeutics has filed a registration statement for the resale of 6.9 million shares of its common stock by existing stockholders.

Calidi Biotherapeutics plans to offer common stock units and warrants to raise capital, as detailed in its S-1/A filing.

Calidi Biotherapeutics plans to offer common stock units and pre-funded warrant units, along with associated warrants, aiming to raise capital for working capital and general corporate purposes.

Calidi Biotherapeutics files an amendment to its Form S-1 registration statement to include updated exhibits and legal opinions related to its proposed offering.

Calidi Biotherapeutics plans to offer common stock units and pre-funded warrant units to raise capital.

Calidi Biotherapeutics seeks to raise up to $24 million through a public offering of common stock and warrants to advance its stem cell-based oncolytic virus platforms.

Calidi Biotherapeutics plans to offer common stock, pre-funded warrants, and common stock purchase warrants in a best efforts offering.

Calidi Biotherapeutics files an amendment to its registration statement related to the issuance of common stock upon warrant exercises and resale by selling securityholders.